Cargando…

Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics

Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or co...

Descripción completa

Detalles Bibliográficos
Autores principales: Musumeci, Domenica, Platella, Chiara, Riccardi, Claudia, Moccia, Federica, Montesarchio, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742822/
https://www.ncbi.nlm.nih.gov/pubmed/29261171
http://dx.doi.org/10.3390/cancers9120174
_version_ 1783288460387287040
author Musumeci, Domenica
Platella, Chiara
Riccardi, Claudia
Moccia, Federica
Montesarchio, Daniela
author_facet Musumeci, Domenica
Platella, Chiara
Riccardi, Claudia
Moccia, Federica
Montesarchio, Daniela
author_sort Musumeci, Domenica
collection PubMed
description Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary structure switches induced by target recognition are suitably translated in a detectable fluorescent signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-invasive in vivo imaging tools for cancer pre- and post-treatment assessment.
format Online
Article
Text
id pubmed-5742822
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57428222017-12-29 Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics Musumeci, Domenica Platella, Chiara Riccardi, Claudia Moccia, Federica Montesarchio, Daniela Cancers (Basel) Review Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary structure switches induced by target recognition are suitably translated in a detectable fluorescent signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-invasive in vivo imaging tools for cancer pre- and post-treatment assessment. MDPI 2017-12-20 /pmc/articles/PMC5742822/ /pubmed/29261171 http://dx.doi.org/10.3390/cancers9120174 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Musumeci, Domenica
Platella, Chiara
Riccardi, Claudia
Moccia, Federica
Montesarchio, Daniela
Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title_full Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title_fullStr Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title_full_unstemmed Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title_short Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics
title_sort fluorescence sensing using dna aptamers in cancer research and clinical diagnostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742822/
https://www.ncbi.nlm.nih.gov/pubmed/29261171
http://dx.doi.org/10.3390/cancers9120174
work_keys_str_mv AT musumecidomenica fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics
AT platellachiara fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics
AT riccardiclaudia fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics
AT mocciafederica fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics
AT montesarchiodaniela fluorescencesensingusingdnaaptamersincancerresearchandclinicaldiagnostics